Decreased plasma urotensin II levels inversely correlate with extent and severity of coronary artery disease

Journal of Geriatric Cardiology

Volumn 4, Issue 2, 2007, Pages 105-110

  Yu, Guolong ^a   Yang, Tianlun ^a   Borlongan, Cesar V ^b   Stahl, Christine E ^c   Xie, Xiaohua ^a   Wang, Yongjin ^d   Xie, Xiumei ^a   Xia, Ke ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c EISENHOWER ARMY MEDICAL CENTER   (United States)

^d CHANGZHI MEDICAL COLLEGE   (China)

Author keywords

Coronary artery atherosclerosis; Coronary heart disease; Urotensin II

Indexed keywords

UROTENSIN II;

ACUTE CORONARY SYNDROME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; SCORING SYSTEM; STABLE ANGINA PECTORIS;

EID: 35948947312     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ong KL, Lam KS, Cheung BM. Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther 2005; 19: 65-75.
2. Maguire JJ, Kuc RE, Wiley KE, et al. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004; 25: 1767-74.
3. Tamura K, Okazaki M, Tamura M, et al. Urotensin II induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci 2003; 72: 1049-60.
4. Watanabe T, Suguoro T, Kanome T, et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 2005; 46: 738-44.
5. Fang SH, Li ZL, Wu HC, et al. Clinical study of plasma urotensin II in patients with coronary heart disease. Di Yi Jun Yi Da Xue Xue Bao 2004; 24: 563-5.
6. Joyal D, Huynh T, Aiyar N, et al. Urotensin-II levels in acute coronary syndromes. Int J Cardiol 2006; 108: 31-5.
7. Tanaka T, Nakamura Y, Nasuno A, et al. Plasma concentrations of monocyte chemoattractant protein 1 (MCP-1) and neopterin in the coronary circulation of patients with coronary artery disease. Circ J 2004; 68: 114-20.
8. Gensini MD, Goffredo G. A more meaningful scoring system for determining the severity of coronary heart disease. Circulation 1983; 51: 606.
9. Braunwald E, Antman EM, Beasley JW, et al. ACC/ AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Am Coll Cardiol 2000;36: 970-1062.
10. Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin II in human heart in-vitro. Br J Pharm 2001; 132: 5-9.
11. Bousette N, Patel L, Douglas SA, et al. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004; 176: 117-23.
12. Rakowski E, Hassan GS, Dhanak D, et al. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol 2005; 39: 785-91.
13. Yang Z, Ming XF. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 2006; 4: 53-65.
14. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001; 12: 383-9.
15. Kemp W, Roberts S, Krum H. Urotensin II: a vascular mediator in health and disease. Curr Vasc Pharmacol 2005; 3: 159-68.
16. Mega JL, Morrow DA, Sabatine MS, et al. Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Am Heart J 2005; 149: 846-50.
17. Karnath BM. Preoperative cardiac risk assessment. Am Fam Physician 2002; 66: 1889-96.
18. Matusushita M, Shichiri M, Fukai N, et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LICPKI. Endocrine 2003; 144: 1825-31.